Literature DB >> 9815630

Toward the validation of aneusomy detection by fluorescence in situ hybridization in bladder cancer: comparative analysis with cytology, cytogenetics, and clinical features predicts recurrence and defines clinical testing limitations.

F F Zhang1, D A Arber, T G Wilson, M H Kawachi, M L Slovak.   

Abstract

Fluorescence in situ hybridization (FISH) is regarded as a potential new tool for the clinical management of bladder cancer that works by detecting cytogenetic aberrations in noncycling, exfoliated cells from bladder irrigations. However, clinical validation steps must be addressed to define the true predictive potential in a clinical setting. Toward the validation of FISH with the use of bladder washings and prior to incorporation into a large, prospective clinical trial, a pilot study was designed to determine its clinical potential, define testing limitations, optimize a panel of probes specific for bladder cancer detection, and outline protocol/data collection parameters. Correlations with standard cytogenetics and clinicopathological features of bladder cancer were investigated. Exfoliated cells obtained from benign bladder washings served as normal controls. The results of this pilot study suggest the following: (a) FISH and cytology are complementary testing procedures; however, the FISH data provided valuable ploidy and specific genotypic information for recurrent tumors in "suspicious" cases; (b) chromosomal aberrations defined by FISH are associated with tumor grade and stage (i.e., simple numerical aberrations were associated with low-grade tumors, and high-grade and invasive tumors exhibited multiple, nonrandom chromosomal aberrations and vast intratumor heterogeneity); (c) somatic pairing or homologous centromeric association can give a false-positive result and appears to be linked to prior therapy; (d) dual hybridization with reference gene-specific probes must be used to control for somatic pairing; and (e) focal, deep muscle invasive lesions, with no surface exposure, may yield false-negative results. The data suggest that FISH analysis, with the use of cells isolated from bladder washings, is a powerful technique holding promise for early cancer detection, monitoring treatment outcome, and predicting recurrence of disease.

Entities:  

Mesh:

Year:  1997        PMID: 9815630

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  5 in total

1.  The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine.

Authors:  I A Sokolova; K C Halling; R B Jenkins; H M Burkhardt; R G Meyer; S A Seelig; W King
Journal:  J Mol Diagn       Date:  2000-08       Impact factor: 5.568

2.  A pilot study of urinary microRNA as a biomarker for urothelial cancer.

Authors:  Jaime Snowdon; Sandy Boag; Harriet Feilotter; Jason Izard; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

3.  Detection of bladder cancer from the urine using fluorescence in situ hybridization technique.

Authors:  Péter Riesz; Gábor Lotz; Csilla Páska; Attila Szendrôi; Attila Majoros; Zsuzsanna Németh; Péter Törzsök; Tibor Szarvas; Ilona Kovalszky; Zsuzsa Schaff; Imre Romics; András Kiss
Journal:  Pathol Oncol Res       Date:  2007-10-07       Impact factor: 3.201

4.  Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated EGLN2-mediated [corrected] oxygen-sensing response.

Authors:  Julie M Koeman; Ryan C Russell; Min-Han Tan; David Petillo; Michael Westphal; Katherine Koelzer; Julie L Metcalf; Zhongfa Zhang; Daisuke Matsuda; Karl J Dykema; Heather L Houseman; Eric J Kort; Laura L Furge; Richard J Kahnoski; Stéphane Richard; Annick Vieillefond; Pamela J Swiatek; Bin Tean Teh; Michael Ohh; Kyle A Furge
Journal:  PLoS Genet       Date:  2008-09-05       Impact factor: 5.917

5.  One-year monitoring of an oligonucleotide fluorescence in situ hybridization probe panel laboratory-developed test for bladder cancer detection.

Authors:  Rima Tinawi-Aljundi; Lauren King; Shannon T Knuth; Michael Gildea; Carrie Ng; Josh Kahl; Jacqueline Dion; Chris Young; Edward W Schervish; J Rene Frontera; Jason Hafron; Kenneth M Kernen; Robert Di Loreto; Joan Aurich-Costa
Journal:  Res Rep Urol       Date:  2015-04-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.